KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Merck's Sac-TMT treatment reduced the risk of death by 32% in a trial for advanced endometrial cancer, according to the company. Merck's stock is currently trading at $141.10, with a 5-day change of -2.87%.

At ESMO '26, Moderna and Merck's cancer vaccine intismeran showed a 42% reduction in melanoma recurrence risk, but Moderna's stock fell. Roche's divarasib outperformed competitors in KRAS-mutated lung cancer. Amgen's Imdelltra combo therapy reduced lung cancer death risk by 58%.

Merck and Kelun-Biotech reported Phase 3 trial results for sacituzumab tirumotecan, showing a 32% reduction in death risk and 6.9-month survival extension in advanced endometrial cancer patients. The FDA accepted Merck's BLA for priority review. Merck specializes in pharmaceuticals, vaccines, and animal health products, with global sales distribution.

Merck and Kelun-Biotech presented Phase III trial results showing their drug sacituzumab govitecan reduced death risk by 33% in advanced endometrial cancer patients. The drug is approved in China and is being tested in 18 global trials, including 10 for women's cancers. Merck aims for U.S. and European approvals, with Keytruda's patent loss expected in 2028.

Merck (MRK) reported that its drug sacituzumab tirumotecan improved survival in advanced endometrial cancer patients in a Phase 3 trial, reducing death risk by 32% and extending median survival by 6.9 months. The FDA accepted a priority review for the drug with a target action date of June 15, 2027. The trial results were presented at the European Society for Medical Oncology Congress 2026.

Merck's Phase 3 KEYNOTE-C93 trial showed KEYTRUDA (pembrolizumab) as monotherapy improved progression-free survival (PFS) to 38.2 months vs. 8.4 months with chemotherapy in dMMR advanced endometrial cancer. The trial met its primary endpoint, reducing disease progression or death risk by 43%. Results were presented at ESMO Congress 2026 and published in The Lancet.